

ALLIANCE UPDATE

Companies	Agreement
Amgen Greater China & Kirin Pharmaceuticals	The two will expand their present joint venture to include the copromotion of erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) in the People's Republic of China. Amgen will produce EPO, while Kirin will make G-CSF.
Anergen & Novo Nordisk	The two will jointly develop products for Type I diabetes, multiple sclerosis (MS), and myasthenia gravis (MG). Novo will fund research, make an \$8 million equity investment in Anergen, and, in return, receive worldwide marketing rights to future products. Anergen will retain copromotion rights in North America for MS and MG products.
AutoImmune & Schering-Plough	The two have ended their rheumatoid-arthritis collaboration, under which Schering funded a phase II trial of AutoImmune's AI-200. AutoImmune retains all rights to the product.
Diatech & Nihon Medi-Physics	Nihon has obtained exclusive rights to market in Japan Diatech's inflammation/infection imaging agent and thrombus imaging agent. Both are synthetic peptides labeled with technetium-99m, and both are in phase I/II trials in the U.S.
Editex & Princeton Diagnostic	The two have signed a letter of intent to merge through a stock exchange. Both focus on abused-substance testing.
Energy BioSystems & Solvay Enzymes	Solvay will provide up to \$500,000 a year in technical resources to Energy BioSystems to develop its biocatalytic desulfurization (BDS) process for the refining industry. Solvay will be Energy BioSystems' sole supplier of BDS-process enzymes.
Enzon & Phytopharmaceutical	The two will develop taxol and taxoid compounds, combining Enzon's Pegnology with Phytopharmaceuticals' chemical-genetics tissue-culture technology. Pegnology involves the attachment of polyethylene glycol to a compound to disguise it from the immune system.
GenPharm International & Eli Lilly	The two will expand their research program to develop human monoclonal antibodies to treat certain cancers. Lilly will make an additional equity investment in GenPharm and increase research payments for development work.
Glycomed & Genentech	The two will extend through 1997 their existing research collaboration to develop carbohydrate-based therapeutics. Under the new agreement, Genentech will provide up to \$24 million in new funding, which includes a \$3.5 million equity investment. Glycomed gets the rights to develop drug candidates for adult respiratory distress syndrome, peritonitis, and organ transplant rejection.
Lidak Pharmaceuticals & Ribic Immunochem Research	Ribic has granted Lidak a license to use its melanoma cell lines to clinically develop Lidak's large multivalent immunogen (LMI) technology, which could improve human responses to various cancer and viral antigens. In exchange, Lidak has granted Ribic an option for an exclusive license to use the LMI technology with its melanoma cell lines for the treatment of melanoma.
Liposome Technology & Zeneca	Zeneca has gained exclusive European marketing rights to Liposome's Amphocil. Amphocil consists of amphotericin B, a broad-spectrum antifungal agent, and sodium cholesteryl sulfate, a water-soluble cholesterol metabolite. Liposome will receive payments that could reach \$20 million.
Oncogene Science & Ciba-Geigy & Pfizer	Oncogene has teamed with Pfizer and Ciba-Geigy to develop Oncogene's transforming growth factor-beta3 (TGF-beta 3). With Pfizer, Oncogene will develop the drug as a chemoprotectant to reduce the toxic side effects of chemotherapy, specifically to prevent oral mucositis. Ciba, which has developed processes to make TGF-beta 3 commercially, will supply the protein.
PerSeptive Biosystems & Vestec	PerSeptive Biosystems, a maker of systems to purify and analyze biomolecules, will purchase Vestec, a leader in mass spectrometry. PerSeptive will give \$4 million of its newly issued stock to Vestec's shareholders.
Repligen & Aaston	In the U.S. District Court for the District of Massachusetts, Aaston was enjoined from working with recombinant protein A, Repligen's patented agent used in antibody purification, diagnostic kits, and research applications. The protein is covered by U.S. patent No. 5,151,350.
Scios Nova & McNeil Pharmaceutical	The two will jointly distribute in the U.S. Haldol Decanoate, a long-acting, injectable version of Haldol haloperidol, an antipsychotic drug used for over 25 years. Haldol Decanoate provides a gradual release of medication over a four-week period for schizophrenic patients. McNeil will manufacture the product and make quarterly payments to Scios based on increasing sales.
Texas Biotechnology & Pharm Discovery	The two will develop oral and injectable formulations for Texas Biotechnology's cardiovascular compounds using Pharmaceutical Discovery's Technosphere microencapsulation system.
Univax Biologics & Genzyme	Univax and Genzyme will develop products to treat cystic-fibrosis-associated lung infections caused by <i>Pseudomonas</i> bacteria. The alliance includes a \$5 million equity investment in Univax by Genzyme.
Vestar & Towers Phytochemical	The two have formed a joint venture to market a generic form of Taxol in selected markets. Towers will supply and produce paclitaxel, the active ingredient in Taxol. Vestar will make and market resulting products.

—Mark Goodstein